Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

Future Market Insights

Key Insight

The benign prostatic hyperplasia (BPH) prostate treatment market is projected to grow from USD 34.2 billion in 2025 to USD 48.7 billion by 2035, at a CAGR of 3.6%. BPH Drugs will dominate with a 61.4% market share, while institutional sales will lead the distribution channel segment with a 67.8% share.

November 03, 2025

Anurag Sharma

324 Pages

Cite this Report

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

https://www.futuremarketinsights.com/reports/benign-prostatic-hyperplasia-bph-and-prostate-treatment-market

License

Buy Now

Summary ToC Companies

Key Players

Allergan plc
Cardinal Health
Eli Lily & Company
GSK
Mylan N.V
NeoTract Inc
NxThera Inc
The Vanguard Group
L'Oréal
Berkshire Hathaway

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

Key Players

Similar Industry Reports